Zacks Investment Research Lowers Repare Therapeutics (NYSE:BLI) to Hold

Zacks Investment Research downgraded shares of Repare Therapeutics (NYSE:BLI) from a buy rating to a hold rating in a report released on Monday, Zacks.com reports.

According to Zacks, “Berkeley Lights Inc. is a Digital Cell Biology company. It focuses on development and commercialization of biotherapeutics and other cell-based products. Berkeley Lights Inc. is based in EMERYVILLE, Calif. “

A number of other brokerages also recently commented on BLI. Cowen started coverage on shares of Repare Therapeutics in a research report on Tuesday, August 11th. They set an outperform rating on the stock. William Blair reissued an outperform rating on shares of Repare Therapeutics in a research report on Tuesday, August 11th. Morgan Stanley started coverage on shares of Repare Therapeutics in a research report on Tuesday, August 11th. They issued an equal weight rating and a $65.00 target price for the company. Finally, JPMorgan Chase & Co. started coverage on shares of Repare Therapeutics in a research report on Tuesday, August 11th. They issued an overweight rating and a $75.00 target price for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Repare Therapeutics has an average rating of Buy and a consensus price target of $74.67.

Shares of BLI opened at $77.14 on Monday. The company’s 50 day moving average is $71.41. Repare Therapeutics has a 52 week low of $50.26 and a 52 week high of $89.67.

Repare Therapeutics (NYSE:BLI) last announced its quarterly earnings data on Tuesday, August 25th. The company reported ($4.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($4.06). The company had revenue of $10.57 million for the quarter, compared to analysts’ expectations of $10.46 million.

Repare Therapeutics Company Profile

Berkeley Lights, Inc, a digital cell biology company that focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. It offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software.

Featured Story: Short Selling Stocks and Day Traders

Get a free copy of the Zacks research report on Repare Therapeutics (BLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.